Table 1 Demographic data and baseline characteristics of study population
Subjects recruited, N (%) | 2118 (100) |
|---|---|
Country, n (%) | |
Poland | 770 (36.4) |
Italy | 547 (25.8) |
Germany | 427 (20.2) |
Spain | 219 (10.3) |
France | 155 (7.3) |
Sex, n (%) | |
Female | 1261 (59.5) |
Male | 857 (40.5) |
Age, years, mean (SD) | 55 (15.8) |
Age category, n (%) | |
0–18 years | 12 (0.6) |
19–59 years | 1191 (56.2) |
≥ 60 years | 915 (43.2) |
Height, meters, mean (SD) | 1.7 (0.1) |
Weight, kg, mean (SD) | 73.7 (15.4) |
BMI, kg/m2, mean (SD) | 25.9 (4.7) |
BMI category, n (%) | |
Underweight (BMI < 18.5) | 41 (1.9) |
Normal (BMI ≥ 18.5–< 25) | 927 (43.8) |
Overweight (BMI ≥ 25–< 30) | 810 (38.2) |
Obese (BMI ≥ 30) | 340 (16.1) |
Comorbidity, n (%) | |
Hypertension | 350 (16.5) |
Allergy | 159 (7.5) |
Previous allergy to iodine media | 12 (0.6) |
Previous allergy to GBCA | 2 (0.1) |
Malignancy/cancer | 140 (6.6) |
Diabetes mellitus | 114 (5.4) |
Neurological symptom | 76 (3.6) |
Heart failure | 26 (1.2) |
Autoimmune disease | 25 (1.2) |
Renal impairment | 16 (0.8) |
eGFR < 30 mL/min/m2 | 2 (0.1) |
Hepatic impairment | 9 (0.4) |
Other | 80 (3.8) |
Premedication, n (%) | |
Steroids | 17 (0.8) |
Antihistamines | 12 (0.6) |
Concomitant medications, n (%) | |
Anti-hypertensives | 309 (14.6) |
Chemotherapy | 102 (4.8) |
Antidiabetic drugs | 94 (4.4) |
Other reported | 225 (10.6) |